• Home
  • About us
  • Log-In
  • Join Us
  • Sitemap
  • Recruit
Á¦Ç°/½ÇÇè Q&A
½ÇÇè±â¹ý
ÀÚ·á½Åû
Ŭ·¹ÀÓ Á¢¼ö
±â±â A/S Á¢¼ö
Ŭ·¹ÀÓ ÁøÇàÁ¶È¸
 Á¦Ç°¾È³»  ¼¼Æ÷¹è¾ç   Stem Cell

hiPSC-Derived Cardiomyocytes

iPS¼¼Æ÷¿¡¼­ À¯·¡µÈ human Cardiomyocytes´Â cariotoxicity Å×½ºÆ®, ¾à¹°°Ë»ç, ¾à¹° À¯È¿¼º È®ÀÎ ¹× ½ÅÁø´ë»ç ¿¬±¸, electrophysiology¿¡ »ç¿ëµË´Ï´Ù. ÇØµ¿µÇ¸é in vitro¿¡¼­ ÀÚ¹ßÀûÀ¸·Î ¹Úµ¿Çϱ⠽ÃÀÛÇϸç, troponinÀ» Æ÷ÇÔÇÑ ½ÉÀå Æ¯ÀÌ ¸¶Ä¿¸¦ ¹ßÇöÇÕ´Ï´Ù.

AXOL
Á¦Ç° ¹®ÀÇÇϱâ
ÀμâÇϱâ

 

  • iPS¼¼Æ÷¿¡¼­ À¯·¡µÈ human Cardiomyocytes´Â cariotoxicity Å×½ºÆ®, ¾à¹°°Ë»ç, ¾à¹° À¯È¿¼º È®ÀÎ ¹× ½ÅÁø´ë»ç ¿¬±¸, electrophysiology¿¡ »ç¿ëµË´Ï´Ù.
  • ÇØµ¿µÇ¸é in vitro¿¡¼­ ÀÚ¹ßÀûÀ¸·Î ¹Úµ¿Çϱ⠽ÃÀÛÇϸç, troponinÀ» Æ÷ÇÔÇÑ ½ÉÀå Æ¯ÀÌ ¸¶Ä¿¸¦ ¹ßÇöÇÕ´Ï´Ù. 
  • Cardiac dysfunction (½ÉºÎÀü) ¹× cardiotoxicity (½É±Ùµ¶¼º) ¿¬±¸¸¦ À§ÇÑ drug testing¿¡µµ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • Primary cell°ú µ¿µîÇÑ ¼öÁØÀÇ °á°ú¸¦ Á¦°øÇÕ´Ï´Ù.
  • ÃÖÀûÀÇ Àü¿ë media¸¦ ÇÔ²² Á¦°øÇÕ´Ï´Ù.




Cat. No. Product Name Quantity
ax2502 Human iPSC-Derived Ventricular Cardiomyocytes (Female) 1 million cells
ax2505 Human iPSC-Derived Ventricular Cardiomyocytes (Male) 1 million cells
ax2520 Human iPSC-Derived Ventricular Cardiomyocytes (Male) 1 million cells
ax2500 Human iPSC-Derived Ventricular Cardiomyocyte Kit (Male)  1 kit (1 million cells)
ax2515 Human iPSC-Derived Atrial Cardiomyocytes (Male) 1 million cells
ax2530-500 Cardiomyocyte Maintenance Medium 500 mL
ax0044 Unlock 25 mL
ax0049 Fibronectin Coating Solution 1 mL




 

  • Immunohistochemistry : Cardiomyocyte ƯÀÌÀûÀÎ marker¸¦ ¹ßÇöÇÕ´Ï´Ù.

        Axol Human iPSC-Derived Ventricular Cardiomyocytes were cultured in Cardiomyocyte Maintenance Medium prior
        to being fixed and stained for the markers Sarcomeric Alpha Actinin and Cardiac Troponin. The cells were 
        counterstained using DAPI to allow visualization of nuclei.


       Expression of Troponin T, atrial natriuretic peptide (ANP) and atrial myosin light chain 2 (MLC2a) was confirmed in
       Axol iPSC-Derived Atrial Cardiomyocytes using immunocytochemistry. Troponin T staining (red) confirmed the
       presence of cardiac myocytes which are responsible for sarcomere contraction. ANP is specifically secreted by
       atrial myocytes upon atrial stretching and MLC2a facilitates cardiac contractility wo. DAPI counterstain. 

  • Beating : ¹è¾ç ÈÄ ÀÚ¹ßÀûÀ¸·Î ¹Úµ¿ÇÕ´Ï´Ù.

 

  • Action potential characteristics : patch clamp¿¡¼­ ÀÚ¹ßÀûÀÎ action potentialÀ» º¸¿©ÁÝ´Ï´Ù.


      Characteristics of spontaneous and evoked action potentials recorded from Axol’s Human iPSC-derived Ventricular
      Cardiomyocytes. Spontaneous (A) and evoked (1 Hz; B) action potentials recorded by whole-cell patch clamp.
      (C) Average action potential parameters for spontaneous and evoked action potentials in control conditions.

  • Core cardiac ion channel pharmacology : INa, ICa,L and IKrÀ» ¹ßÇöÇÕ´Ï´Ù.


       Axol’s Human iPSC-derived Ventricular Cardiomyocytes express the core cardiac ion channels INa, ICa,L and IKr.
      (A) Representative traces of evoked action potentials recorded under control conditions (grey) and in the presence
      of 100 μM Lidocaine (green), 100 nM Nifedipine (blue) or 50 nM Dofetilide (red), which show expected effects on
      action potential amplitude and duration. B) Average effect of each compound on spontaneous action potential
      parameters, presented as percent of control ± SEM, N ≥ 4. Statistical significance calculated by a paired
      two-tailed Student’s t-test (* p<0.05, ** p<0.01, *** p<0.001).

  • Calcium Imaging : Ä®½·À̹Ì¡ ºÐ¼®¿¡ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.


  • Modeling Arrhythmias : ºÎÁ¤¸Æ ºÐ¼®¿¡ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

 

           Axol’s Human iPSC-Derived Ventricular Cardiomyocytes were treated with doxorubicin (control, 500 nM, 100 nM
           and 50 nM). There was a dose-dependent response at 13 h and 24 h post-treatment with doxorubicin.
           Arrhythmias and loss of beating amplitude were seen at lower doxorubicin concentration, whereas higher 
           doxorubicin concentrations resulted in tachycardia and ultimately cell death. Data kindly provided by
           Dr J. Maynes, University of Toronto.

 

   Protocols        

ÁÖ¹®Á¤º¸(Ordering Information)
CATNUM PRODUCT SIZE
ax2530-500Cardiomyocyte Maintenance Medium500 mL
ax0049Fibronectin Coating Solution1 mL
ax2515Human iPSC-Derived Atrial Cardiomyocytes (Male)1 vial
ax2500Human iPSC-Derived Ventricular Cardiomyocyte Kit (Male) 1 kit
ax2502Human iPSC-Derived Ventricular Cardiomyocytes (Female)1 vial
ax2505Human iPSC-Derived Ventricular Cardiomyocytes (Male)1 vial
ax2520Human iPSC-Derived Ventricular Cardiomyocytes (Male)1 vial
ax0044Unlock25 mL